0000000000085478

AUTHOR

Roberta Fantozzi

showing 9 related works from this author

A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia

2021

The prevalence of trigeminal neuralgia (TN) in patients with Multiple Sclerosis (MS) is higher than in the general population and its management can be particularly challenging due to a number of reasons including high recurrence rates, lack of MS-specific treatment guidelines and uncertainties about pain pathophysiology. Aim of this cross-sectional, multicentre survey was to gather information on the current treatment modalities and options of MS-related TN across 23 Italian MS centres. Initial medical management (carbamazepine or oxcarbazepine) of MS-related TN was fairly homogeneous throughout Italian centres. The most commonly available surgical procedure was microvascular decompression…

medicine.medical_specialtyMultiple Sclerosismultiple sclerosis; trigeminal neuralgiaCross-sectional studymedicine.medical_treatmentPopulationMicrovascular decompressionHealth Services Accessibility03 medical and health sciences0302 clinical medicineRetrospective StudieTrigeminal neuralgiaMultiple SclerosimedicineHumans030212 general & internal medicineIntensive care medicineeducationOxcarbazepineRetrospective StudiesCross-Sectional Studieeducation.field_of_studybusiness.industryMultiple sclerosisRetrospective cohort studyTrigeminal Neuralgiamedicine.diseaseCross-Sectional StudiesTreatment OutcomeItalyNeurologyMulticenter surveyNeurology (clinical)businessMultiple Sclerosis; Trigeminal neuralgia; Cross-Sectional Studies; Health Services Accessibility; Humans; Italy; Retrospective Studies; Treatment Outcome; Multiple Sclerosis; Trigeminal NeuralgiaTrigeminal neuralgia030217 neurology & neurosurgeryHumanmedicine.drugJournal of the Neurological Sciences
researchProduct

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

2021

Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system. A novel coronavirus, namely SARS-CoV-2, has been recently responsible for the highly infectious disease referred as COVID-19, rapidly spreading all over the world. Many vaccines have been developed to control COVID-19 pandemic, including the mRNA vaccines Pfizer/BioNTech (BNT162b2) and Moderna (mRNA1273).1 The vaccination of people with MS (pwMS) has been recommended by several national and international MS societies. However, effectiveness and safety of anti-COVID-19 mRNA vaccines in MS need to be confirmed. The aim of this study was to evaluate the short-term risk of clinical relapses in pwMS in …

Pediatricsmedicine.medical_specialtyeducation.field_of_studyExpanded Disability Status ScaleCoronavirus disease 2019 (COVID-19)business.industryMultiple sclerosisCOVID-19; multiple sclerosis; neuroimmunologyPopulationCOVID-19neuroimmunologymedicine.diseasemultiple sclerosisVaccinationPsychiatry and Mental healthInfectious disease (medical specialty)multiple sclerosiPandemicmedicineSurgeryObservational studymultiple sclerosis neuroimmunology COVID-19Neurology (clinical)businesseducation
researchProduct

Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.

2021

Objective: To identify baseline factors associated with disease activity in patients with relapsing–remitting multiple sclerosis (RRMS) under teriflunomide treatment. Methods: This was an independent, multi-centre, retrospective post-marketing study. We analysed data of 1,507 patients who started teriflunomide since October 2014 and were regularly followed in 28 Centres in Italy. We reported the proportions of patients who discontinued treatment (after excluding 32 lost to follow-up) and who experienced clinical disease activity, i.e., relapse(s) and/or confirmed disability worsening, as assessed by the Expanded Disability Status Scale (EDSS). Decision tree-based analysis was performed to i…

medicine.medical_specialtyNeurologyMultiple SclerosisToluidinesHydroxybutyratesOral drugsDiseaseRelapsing-RemittingSettore MED/26Pregnancy planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInternal medicineTeriflunomideTeriflunomideNitrilesmedicineHumans030212 general & internal medicineAdverse effectRetrospective StudiesExpanded Disability Status Scalebusiness.industryMultiple sclerosismedicine.diseaseSettore MED/26 - NEUROLOGIANeurologychemistryTolerabilityItalyMultiple sclerosis; Oral drugs; Teriflunomide; Crotonates; Humans; Hydroxybutyrates; Italy; Nitriles; Retrospective Studies; Toluidines; Multiple Sclerosis; Multiple Sclerosis Relapsing-RemittingCrotonatesNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology
researchProduct

Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study

2019

Abstract Background The prevalence of trigeminal neuralgia (TN) in Multiple Sclerosis (MS) patients is higher than in the general population and its management can be particularly challenging. Our aim is to describe the characteristics, treatment and prognostic factors of MS-related TN in a retrospective multicentre study. Methods Neurologists members of the RIREMS group (Rising Researchers in MS) enrolled MS patients with a TN diagnosis and filled out a spreadsheet comprising their clinical data. Results Population consisted of 298 patients. First-choice preventive treatments were carbamazepine and oxcarbazepine. A surgical procedure was performed in 81 (30%) patients, most commonly gamma …

Pediatricsmedicine.medical_treatmentmultiple sclerosismicrovascular decompression surgerytime factors0302 clinical medicineRadiofrequency thermocoagulationTrigeminal neuralgiaMultiple SclerosiOutcome Assessment Health Careitalymiddle agedpain030212 general & internal medicineOxcarbazepinehumanseducation.field_of_studytrigeminal neuralgiaadultDisability; Multiple Sclerosis; Pain; Trigeminal neuralgiaradiosurgeryGeneral MedicineAnalgesics Non-Narcotichealth carefollow-up studiesSettore MED/26 - NEUROLOGIAagedretrospective studiesfemaleNeurologydisability; multiple sclerosis; pain; trigeminal neuralgia; adult; aged; analgesics non-narcotic; female; follow-up studies; humans; italy; male; microvascular decompression surgery; middle aged; multiple sclerosis; radiosurgery; retrospective studies; severity of illness index; sex factors; time factors; trigeminal neuralgia; neurosurgical procedures; outcome assessment health careanalgesicsTrigeminal neuralgiamedicine.drugmedicine.medical_specialtyMultiple SclerosisPopulationPainMicrovascular decompression03 medical and health sciencesmalemedicineseverity of illness indexeducationoutcome assessmentDisabilitybusiness.industryMultiple sclerosisCarbamazepinemedicine.diseaseneurosurgical proceduresDiscontinuationsex factorsdisabilitynon-narcoticNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.

2018

In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data of patients regularly attending 21 Italian MS Centres who started a self-injectable or an oral DMT in 2015 were collected to: (1) estimate the proportion of patients discontinuing the treatment; (3) explore reasons for discontinuation; (3) identify baseline predictors of treatment discontinuation over a follow-up period of 12 months. We analyzed data of 1832 consecutive patients (1289 women, 543 men); 374 (20.4%) of them discontinued the prescrib…

MaleInjectionTime FactorsPatient Dropoutdisease-modifying therapies; multiple sclerosis; outcome measurement; persistence to treatment; quality of lifeAdministration OralSelf AdministrationSex FactorKaplan-Meier EstimateRelapsing-Remittingmultiple sclerosisImmunologic Factor0302 clinical medicineQuality of lifeRetrospective StudieRisk FactorsMedicine030212 general & internal medicineDisease-modifying therapiedisease-modifying therapiesDisease-modifying therapies Multiple sclerosis Outcome measurement Persistence to treatment Quality of life Administration Oral Adult; Female Follow-Up Studies Humans Immunologic Factors Injections Kaplan-Meier EstimateMale Multiple Sclerosis Relapsing-Remitting Patient Dropouts Prognosis Proportional Hazards Models Retrospective Studies Risk Factors Self Administration Sex Factors Time FactorsHazard ratioPrognosisNeurologyTolerabilityAdministrationSettore MED/26 - NeurologiaFemaleoutcome measurementHumanOralAdultmedicine.medical_specialtyPatient DropoutsTime FactorPrognosiFollow-Up StudieInjections03 medical and health sciencesRoute of administrationMultiple Sclerosis Relapsing-RemittingSex FactorsInternal medicineHumansImmunologic FactorsMultiple sclerosiAdverse effectProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelRisk FactorRetrospective cohort studyDiscontinuationDisease-modifying therapies; Multiple sclerosis; Outcome measurement; Persistence to treatment; Quality of life; Administration Oral; Adult; Female; Follow-Up Studies; Humans; Immunologic Factors; Injections; Kaplan-Meier Estimate; Male; Multiple Sclerosis Relapsing-Remitting; Patient Dropouts; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Self Administration; Sex Factors; Time Factorsquality of lifeProportional Hazards Modelpersistence to treatmentNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesJournal of neurology
researchProduct

Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

2021

Background and purpose: Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS. Methods: One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected. Results: TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11–68 years, interquartile range [IQR]: 38 years). At onset, 52% of …

Maletumefactive demyelinating lesions (TDLs)0302 clinical medicineRetrospective StudieInterquartile rangedifferential diagnosis030212 general & internal medicineProspective StudiesYoung adultProspective cohort studyChildtreatmentTumefactive multiple sclerosiTumefactive demyelinating lesionsDemyelinating DiseaseMiddle AgedMagnetic Resonance ImagingDifferential diagnosis Multiple sclerosis Tumefactive demyelinating lesions Tumefactive multiple sclerosisNeurologydifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosisFemaleHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentdifferential diagnosiSettore MED/26Multiple sclerosis03 medical and health sciencesYoung AdultTumefactive multiple sclerosisOligoclonal BandInternal medicinemedicineHumansMultiple sclerosiTumefactive multiple sclerosisTumefactive multiple sclerosis (TuMS)AgedRetrospective StudiesTumefactive demyelinating lesionExpanded Disability Status Scalebusiness.industryOligoclonal BandsRetrospective cohort studyOdds ratiomedicine.diseaseConfidence intervalProspective Studiedifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosis; Adolescent; Adult; Aged; Child; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligoclonal Bands; Prospective Studies; Retrospective Studies; Young Adult; Demyelinating Diseases; Multiple SclerosisprognosisNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating Diseases
researchProduct

Informing MS patients on treatment options: a consensus on the process of consent taking

2020

Abstract\ud In the last years, change in multiple sclerosis (MS) therapeutic scenario has highlighted the need for an improved doctor-patient communication in advance of treatment initiation in order to allow patient’s empowerment in the decision-making process.\ud Aims\ud The aims of our project were to review the strategies used by Italian MS specialists to inform patients about treatment options and to design a multicentre shared document that homogenizes the information about disease-modifying treatment (DMTs) and the procedure of taking informed consent in clinical practice.\ud Results\ud The new resource, obtained by consensus among 31 neurologists from 27 MS Centres in Italy with the…

medicine.medical_specialtyConsensusProcess (engineering)media_common.quotation_subjectDermatologyDisease modifying treatment; Informed consent; Multiple sclerosisMultiple sclerosis03 medical and health sciences0302 clinical medicineResource (project management)Informed consentDisease modifying treatmentmedicineHumans030212 general & internal medicineInformed consentEmpowermentmedia_commonPhysician-Patient Relationsbusiness.industryTreatment optionsGeneral MedicineClinical PracticePsychiatry and Mental healthItalyFamily medicineDisease modifying treatment; Informed consent; Multiple sclerosis; Consensus; Humans; Italy; Physician-Patient Relations; Informed Consent; Multiple SclerosisSettore MED/26 - NeurologiaNeurology (clinical)Decision processbusiness030217 neurology & neurosurgery
researchProduct

Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis.

2022

ObjectiveAssessing the risk of clinical and radiological reactivation during pregnancy and post partum in women with multiple sclerosis (MS) treated with natalizumab (NTZ) throughout pregnancy (LONG_EXP) compared with women interrupting treatment before (NO_EXP) and within >−30 days and ≤90 days from conception (SHORT_EXP), and describing newborns’ outcomes.MethodsMaternal clinical and radiological outcomes and obstetric and fetal outcomes were retrospectively collected and compared among groups (NO_EXP, SHORT_EXP, LONG_EXP). Predictors of clinical and radiological reactivation were investigated through univariable and multivariable analysis.Results170 eligible pregnancies from 163 women…

Psychiatry and Mental healthSettore MED/26 - NEUROLOGIAobstetricsmultiple sclerosiobstetricSurgeryNeurology (clinical)MRI; multiple sclerosis; obstetricsSettore MED/26multiple sclerosisMRIJournal of neurology, neurosurgery, and psychiatry
researchProduct

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis

2018

ObjectiveTo investigate clinical and radiological outcomes of women with relapsing-remitting multiple sclerosis (RRMS) undergoing abortion.MethodsAn independent, multicentre retrospective study was conducted collecting data from eight Italian MS centres. We compared the preconception and postabortion annualised relapse rate (ARR) and number of Gadolinium enhancing (Gd+) lesions, by analyses of covariance. Variables associated with postabortion clinical and MRI activity were investigated using Poisson regression models; each abortion was considered as a statistical unit.ResultsFrom 1995 to 2017, we observed 188 abortions (17 elective) in 153 women with RRMS. Abortions occurred after a mean t…

AdultMalemedicine.medical_specialtyMultiple SclerosisGadoliniumNeuroimagingDiseaseRelapsing-RemittingAbortionSettore MED/26annualised relapse rateYoung Adult03 medical and health sciencessymbols.namesakeMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrencemedicineHumansPoisson regressionRetrospective StudiesInflammationPregnancy030219 obstetrics & reproductive medicinebusiness.industryObstetricsMultiple sclerosisInducedAbortionAbortion InducedRetrospective cohort studymedicine.diseaseMagnetic Resonance Imaginggadolinium enhancing lesionDiscontinuationPsychiatry and Mental healthPregnancy Maintenancemultiple sclerosisymbolsSettore MED/26 - NeurologiaFemaleSurgerypregnancyNeurology (clinical)business030217 neurology & neurosurgeryabortion; annualised relapse rate; gadolinium enhancing lesion; multiple sclerosis; pregnancyJournal of Neurology, Neurosurgery & Psychiatry
researchProduct